(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 October 2025 (09.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/212726 A2

(51) International Patent Classification:
C07K 16/22 (2006.01) *A61K 39/00* (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2025/022664

(22) International Filing Date:
02 April 2025 (02.04.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/574,664 04 April 2024 (04.04.2024) US

(71) Applicant: **COMPASS THERAPEUTICS, INC.** [US/US]; 80 Guest Street, Suite 601, Boston, Massachusetts 02135 (US).

(72) Inventors: **ALBU, Diana**; c/o Compass Therapeutics, Inc., 80 Guest Street, Suite 601, Boston, Massachusetts 02135 (US). **ULUMBEN, Amy Daniel**; c/o Compass Therapeutics, Inc., 80 Guest Street, Suite 601, Boston, Massachusetts 02135 (US). **VISINTIN, Alberto**; c/o Compass Therapeutics, Inc., 80 Guest Street, Suite 601, BOSTON, Massachusetts 02135 (US). **SACHSENMEIER, Kris**; c/o Compass Therapeutics, inc., 80 Guest Street, Suite 601, Boston, Massachusetts 02135 (US). **SCHUETZ, Thomas**; c/o Compass Therapeutics, Inc., 80 Guest Street, Suite 601, Boston, Massachusetts 02135 (US). **DUFFY, Rachel**; c/o Compass Therapeutics, Inc., 80 Guest Street, Suite 601, Boston, Massachusetts 02135 (US). **GONG, Bing**; c/o Compass Therapeutics, Inc., 80 Guest Street, Suite 601, Boston, Massachusetts 02135 (US).

(74) Agent: **LENTZ, Shannon** et al.; Crowell & Moring LLP, 1001 Pennsylvania Ave NW, Washington, District of Columbia 20004 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: COMBINATION OF ANTIBODIES TARGETING DLL4/VEGF AND CD137 AGONISTS OR ANTI-PD1/ANTI-PD-L1 ANTIBODIES FOR THE TREATMENT OF CANCER

(57) Abstract: The present disclosure relates to, *inter alia*, methods of combining antibodies and immunotherapy for treating, or ameliorating one or more symptoms of cancer.




Fig.2

[Continued on next page]

WO 2025/212726 A2

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*